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Aim: Positron emission tomography (PET) imaging is a useful tool for assisting in
correct differentiation of tumor progression from reactive changes, and the radiolabeled
amino acid analog tracer O-(2-18F-fluoroethyl)-L-tyrosine (FET)-PET is amongst the most
frequently used. The FET-PET images need to be quantitatively correct in order to be used
clinically, which require accurate attenuation correction (AC) in PET/MRI. The aim of this
study was to evaluate the use of the subject-specific MR-derived ACmethod RESOLUTE
in post-operative brain tumor patients.
Methods: We analyzed 51 post-operative brain tumor patients (68 examinations,
200 MBq [18F]-FET) investigated in a PET/MRI scanner. MR-AC maps were acquired
using: (1) the Dixon water fat separation sequence, (2) the ultra short echo time (UTE)
sequences, (3) calculated using our new RESOLUTE methodology, and (4) a same day
low-dose CT used as reference “gold standard.” For each subject and each AC method
the tumor was delineated by isocontouring tracer uptake above a tumor(T)-to-brain
background (B) activity ratio of 1.6. We measured B, tumor mean and maximal activity
(TMEAN, TMAX), biological tumor volume (BTV), and calculated the clinical metrics TMEAN/B
and TMAX/B.
Results: When using RESOLUTE 5/68 studies did not meet our predefined acceptance
criteria of TMAX/B difference to CT-AC < ±0.1 or 5%, TMEAN/B < ±0.05 or 5%, and
BTV < ±2mL or 10%. In total, 46/68 studies failed our acceptance criteria using Dixon,
and 26/68 using UTE. The 95% limits of agreement for TMAX/B was for RESOLUTE
(−3%; 4%), Dixon (−9%; 16%), and UTE (−7%; 10%). The absolute error when
measuring BTV was 0.7 ± 1.9mL (N.S) with RESOLUTE, 5.3 ± 10mL using Dixon, and
1.7 ± 3.7mL using UTE. RESOLUTE performed best in the identification of the location
of peak activity and in brain tumor follow-up monitoring using clinical FET PET metrics.
Ladefoged et al. PET/MR-AC in Brain Tumor Patients
Conclusions: Overall, we found RESOLUTE to be the AC method that most robustly
reproduced the CT-AC clinical metrics per se, during follow-up, and when interpreted into
defined clinical use cut-off criteria and into the patient history. RESOLUTE is especially
suitable for brain tumor patients, as these often present with distorted anatomy where
other methods based on atlas/template information might fail.
Keywords: PET/MR, attenuation correction, brain tumors, bone density, RESOLUTE
INTRODUCTION
Conventional MRI including T1 weighted imaging after
gadolinium contrast is the current method of choice for
diagnosis and follow-up of cerebral brain tumors (Galldiks
et al., 2015b). However, there are several limitations of clinical
importance using MRI. Tumor relapse typically presents as a
contrast-enhanced region that can be difficult to distinguish
from e.g., post-operative changes or radiation damage (Mullins
et al., 2005; Vander Borght et al., 2006; Galldiks et al., 2015a).
In gliomas, these post-operative changes are difficult to predict
as they occur at different time points after treatment, from
within the first 3 months of radiotherapy up to several years
after (Galldiks et al., 2015b). Furthermore, because of the known
capacity of gliomas to infiltrate surrounding tissue, contrast
enhanced MRI does not accurately reflect the actual tumor
extension (Watanabe et al., 1992; Buchmann et al., 2016).
Positron emission tomography (PET) imaging is a useful tool
for assisting in the correct differentiation of tumor progression
from reactive changes. Several tracer options exist to image
gliomas, where the radiolabeled amino acid analog tracer O-
(2-18F-fluoroethyl)-L-tyrosine (FET)-PET is amongst the most
frequently used due to its ease of synthesis, high in vivo stability,
and its fast accumulation into brain tumors independent of
blood-brain barrier disruption (Vander Borght et al., 2006; Albert
et al., 2016). FET-PET is superior to CT and MRI for estimating
the true tumor extent both in low- and high-grade gliomas
(Kracht et al., 2004; Vander Borght et al., 2006), and the post-
resection PET volume, the biological tumor volume (BTV), is a
significant prognostic factor for overall survival in glioblastoma
multiforme (Poulsen et al., 2017).
The FET-PET images need to be quantitatively correct in
order to be used clinically. To achieve this, we need accurate
attenuation correction (AC) in PET/MRI (Vander Borght et al.,
2006). Several authors have reported shortcomings of the vendor-
provided AC techniques, either due to bone not being accounted
for (Andersen et al., 2014), or due to incorrect bone segmentation
and density assignment (Dickson et al., 2014). Several methods
have been proposed for improving AC of the brain (Ladefoged
et al., 2017), with varying degree of detail in regards to
bone representation. Some of the best performing methods are
atlas/template-based, where a pseudo-CT is build either from a
single subject (Izquierdo-Garcia et al., 2014) or by combining CT
data from a database of subjects with locally similar MR images
(Burgos et al., 2014). This strategy is also adopted in the two
simultaneous PET/MRI currently available; The Signa PET/MRI
(GEHealthcare,WaukeshaWI, USA) uses an atlas-basedmethod
for the brain (Wollenweber et al., 2013), and the Biograph mMR
(Siemens Healthcare GmbH, Erlangen, Germany) uses an atlas-
based method for the whole-body (Paulus et al., 2015; Koesters
et al., 2016).
An alternative and more adaptable method is the
segmentation-based, where the AC map is constructed from
a segmentation of one or multiple MR images, e.g., as it was
introduced with the MR-AC method RESOLUTE (Ladefoged
et al., 2015).
One limitation in previously published evaluations of the
effects of various AC strategies has been the lack of recognized
metrics in general clinical use. Instead the evaluations have
been based on general neuroscience image processing strategies
suited for managing large data sets on a group level. This has
delivered measures of e.g., global activity, or in template-based
predefined anatomical regions, that, although useful, is not in
clinical diagnostic use (Ladefoged et al., 2017). For new PET/MRI
AC strategies to be generally accepted in the clinical community
it is important that performance is evaluated on a patient-by-
patient basis using accepted and well-defined clinical metrics.
In this study we aim to compare the effects of the various
AC methods on FET-PET images including RESOLUTE in
post-surgery brain tumor patients with metal implants. Neuro-
oncology FET-PET imaging is particularly well suited as it
primarily relies on a number of well-defined and generally
accepted biological metrics and diagnostic cut-offs, and less on
a subjective clinical reading.
MATERIALS AND METHODS
Patients
The department archive was screened for patients who
underwent surgery for histologically proven glioma or
intracerebral metastasis and had simultaneously acquired
[18F]-FET-PET and MRI using our PET/MRI system (Siemens
Biograph mMR, Siemens Healthcare, Erlangen, Germany)
(Delso et al., 2011) between February 2013 and April 2016,
and 267 FET-PET scans in total were identified. All patients
were referred clinically or were part of research protocols, some
of which have been published (Henriksen et al., 2016a,b). All
investigations were performed on the expressed request and
written documentation of the responsible treating clinician,
and after obtaining both written and informed consent from
the patient at the time of their admission to the hospital for
their data to be used in future research. There was no conflict
with the Declaration of Helsinki. The regional ethics committee
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(Scientific Ethics Committee of the Capital Region) has reviewed
a synopsis of the protocol, but has waived the need for written
informed consent to be obtained from research participants
due to the retrospective nature of the study as per national
regulations (H-4-2014-FSP). We selected all patients from the
cohort with an age above 18 years and a BTV above 1mL. A
total of 52 patients met the inclusion criteria. All had metal
implants with titanium alloy clamps in 3–4 trepanation holes for
fixation of craniotomized cranial bone flaps (Craniofix R©) and/or
titanium alloy mesh cranioplasty used in patients with larger
cranial calvarial or skull base craniotomy defects. The implants
are non-ferromagnetic and MRI-conditional up to 3.0 Tesla,
and are known to compromise MR image quality by producing
susceptibility artifacts in the near vicinity dependent onmagnetic
field strength and sequence, usually in the order of 5 mm on T1
MPRAGE. Thus, one repeated examination was removed from
group-, but not individual, analysis because of a large signal void
from a titanium alloy mesh (Figure 1). One patient was excluded
from analysis because of unreliable separation of tumor tissue
and physiological skin uptake across AC methods. Fourteen of
the included patients had one or more repeated examinations
performed (mean difference to baseline: 67 ± 35 days). This
resulted in a total of 68 examinations from 51 patients (Table 1).
The patients were referred for response assessment during
chemotherapy and evaluation of possible tumor recurrence or
radiation damage. Primary histology was based on the 2007
World Health Organization (WHO) Classification of Tumors of
the Central Nervous System (Louis et al., 2007).
Acquisition of CT
A reference low-dose CT image (120 kVp, 36 mAs, 74 slices,
0.6 × 0.6 × 3 mm3 voxels) of the head using a whole-body
PET/CT system was used (Biograph TruePoint 40 and Biograph
TruePoint 64, Siemens Healthcare) (Jakoby et al., 2009). The CT
images were acquired either on the same day as the PET/MRI
examination, or at a previous examination with no brain altering
surgery in-between.
Acquisition of MRI
The scan protocol included two vendor-provided AC methods: a
two-point DIXON-VIBE AC sequence with repetition time (TR)
2,300 ms, echo time 1 (TE1) 1.23 ms, echo time 2 (TE2) 2.46ms,
flip angle 10 degrees, coronal orientation, 19 s acquisition time,
voxel size of 2.6× 2.6× 3.12mm3, and a UTE AC sequence with
TR/TE1/TE2 = 11.94/0.07/2.46 ms, a flip angle of 10 degrees,
axial orientation, 100 s acquisition time, field of view (FOV) of
300mm2, reconstructed on 192 × 192 × 192 matrices (1.6 × 1.6
× 1.6 mm3 voxels). The 60 scans performed after October 2013
used the Siemens MR scanner software version VB20P, whereas
the 8 scans examined before used software version VB18P, which
included a work-in-progress version of the UTE sequence.
Acquisition of FET-PET
Patients were positioned head first with their arms down on
the fully integrated PET/MRI system. Data were acquired 20–
40 min after injection of 200 MBq FET over a single bed
position of 25.8 cm covering the head and neck. For the purpose
of this study, the PET data from the PET/MRI acquisition
were reconstructed oﬄine (E7tools, Siemens Medical Solutions,
Knoxville, USA) using 3D Ordinary Poisson-Ordered Subset
Expectation Maximization (OP-OSEM) with 4 iterations, 21
subsets, zoom 2.5, and 5 mm Gaussian post filtering on 344 ×
344matrices (0.8× 0.8× 2.0mm3 voxels) in line with the clinical
protocol used at our institution. For all images default random,
scatter, and dead time correction were applied.
Attenuation Correction Methods
Four methods for AC were applied to the data. First,
vendor-provided MR-based attenuation maps, MRACDIXON and
MRACUTE, were derived using the DIXON VIBE sequence
(Martinez-Möller et al., 2009) and the UTEMR sequence (Catana
et al., 2010), respectively. Next, the MR-AC method RESOLUTE
was calculated (Ladefoged et al., 2015). In short, the image-
derived method segments the original UTE Echo MR images
for air, soft tissue, brain, cerebral spinal fluids, and continuous
patient specific bone values. Finally, for each subject, the CT
image was co-registered to the T1w image, and was used as our
gold standard AC reference following conversion of Hounsfield
Units as implemented on the Siemens PET/CT system (Carney
et al., 2006): CT-AC.
Image Processing and Analysis
The simultaneously acquired FET-PET images were inherently
co-registered to the corresponding T1 weighted (T1w) MRI. A
3D “banana” shaped background region (B) of interest (ROI) was
delineated in healthy appearing gray and white matter at a level
above the insula in the contralateral hemisphere to the tumor. An
identical background ROI was used for all 4 AC methods. The
BTV of FET-PET was measured using a 3D auto-contour using
Mirada XD software (MiradaMedical, Oxford, United Kingdom)
defining tumor tissue at a unique threshold above 1.6 of the
mean standardized uptake value (SUV) in the background ROI
(Floeth et al., 2005) for each ACmethod separately. Extratumoral
areas with high FET uptake, e.g., vascular structures, pineal body
and skin, were identified on either the T1w or PET image and
removed from evaluation.
The accuracy of the different AC methods in FET-PET
was assessed on a patient-by-patient basis using the most
commonly used semi-quantitative clinical metrics in the
diagnostic workflow. Although, the low-grade gliomas in the
study had not received radiotherapy, and other thresholds may
be more applicable to metastases (Ceccon et al., 2016), the data
from all the patients can be used to simulate the effects of
variations in AC techniques on regional activity concentration
and clinical metrics. The PET values in the four BTV’s were
measured as tumor mean (TMEAN), and tumor max (TMAX),
and the ratios TMEAN/B and TMAX/B were calculated. The ratios
were compared across the different MR-AC methods to the
ratio measured with the reference CT-AC. These metrics are
commonly used as a criterion to identify active tumor tissue
from reactive changes. In gliomas post-radiotherapy a TMAX/B
< 2.0 is often considered reactive tissue (Langen et al., 2011),
and a TMAX/B > 2.4 is considered indicative of active tumor
tissue (Popperl et al., 2006; Galldiks et al., 2015a); while ratios
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FIGURE 1 | (A) The only case in the series where RESOLUTE gave clinical unacceptable results. Not included in the quantitative analyses. The titanium alloy mesh
implant give rise to a cigar shaped signal void along the mesh, and a spherical void at it posterior adhesion screw. Bone is build into the lateral frontal subcutaneous
tissue swelling and medially into intracranial soft tissue. The FET PET activity distribution shows a significant defect at the posterior signal void. (B) A patient with the
same type of metal implant but with a minor non-significant signal void in the MR image. Notice, the CTs shown here are before resampling to PET resolution and
before blurring is applied to better display the implant. The RESOLUTE attenuation map calculation can be finished in 5 min during the PET acquisition allowing for
quality assurance and corrective measures, such as low dose CT of the head for attenuation correction, before the patient leaves the department.
in-between could be in either category. For TMEAN/B an optimal
cut-off of ∼>2.0 combined with time activity curve shape has
been found for differentiation between glioma and metastatic
recurrence and treatment damage (Galldiks et al., 2015b; Ceccon
et al., 2016). However, in clinical practice these cut-off levels
should only be considered approximations as the evaluation
will also be influenced by a number of other factors including
reconstruction parameters, activity morphology, previous and
current treatment, structural changes, and prior imaging results.
Image Metrics and Acceptance Criteria
Our acceptance criteria were absolute differences of< ±0.05 and
0.1 or 5%, for the TMEAN/B and TMAX/B ratios, respectively, and
±2mL or 10% for the BTV. These were based on differences
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TABLE 1 | Characteristics of patients and lesions studied with 18F-FET PET/MRI.
Characteristic Patients
Patients 51
18F-FET PET scans 68
Sex
Female (%) 20 (39)
Male (%) 31 (61)
Median age (range) 56 (24–82)
HISTOLOGY AT INITIAL DIAGNOSIS (%)
Metastatic carcinoma 2 (4)
Hemangiopericytoma 1 (2)
Metastatic melanoma 1 (2)
Low-grade glioma-unspecified 1 (2)
Astrocytoma grade II 1 (2)
Oligo-astroglioma grade II 3 (8)
Oligodendroglioma grade II 3 (8)
Anaplastic oligodendroglioma grade III 9 (18)
Anaplastic astrocytoma grade III 2 (4)
Glioblastoma multiforme grade IV 28 (55)
LOCATION OF TUMOR (%)
Cortically 26 (51)
Deep-seated 22 (43)
Vermis 3 (8)
in clinical practice that may be considered clinically relevant in
identifying biologically active tumor tissue or treatment related
change in activity (Piroth et al., 2011). The mix of both an
absolute and relative cut-off reflects that larger absolute change is
acceptable in large or very active tumors. There are no test-retest
data available for FET-PET imaging.
Peak TMAX location
An important FET-PET indication is in biopsy target planning
with the identification of the biologically most aggressive
component (“hot spots”) in heterogeneous glioma on MRI to
optimize the diagnostic accuracy (Messing-Junger et al., 2002;
Floeth et al., 2005; Ewelt et al., 2011; Kunz et al., 2011). The
biopsy target is usually defined as the peak voxel of TMAX
within the tumor. This location was mapped for the different AC
reconstructions and compared to the reference. Our criterion was
set at <10mm, as this corresponds to the approximate size of an
average stereotactic biopsy.
Biological tumor volume
The BTV has neuro-oncological significance on several levels
used both in selected cases as an adjunct in radiotherapy planning
(Moller et al., 2016), but also in evaluating treatment response
(Albert et al., 2016). Thus, both the BTV value itself and the
geometric position and shape needs to be evaluated across AC
methods. We analyzed the tumor contours relative to the CT-AC
reference using the Jaccard similarity metric, and a measurement
of shape deviations, found by thresholding the smoothed tumor
difference image. This is in recognition that the clinical impact of
a volume change caused by a focal structure is larger than volume
change caused by a one-voxel displacement along the tumor
contour.
Statistical analysis
For each clinical metric, TMEAN/B, TMAX/B, and BTV, we
calculated the mean difference, 95% confidence intervals (CI)
and limits of agreement on the log-transformed data, as the data
was found to have a log normal distribution. Exponentiation
was applied to these results to express the differences as
ratios on the original scale and report them as percentage
differences:
CI = 100 · (ed±
1.96SDd√
n −1) (1)
Limits of agreement = 100 · (ed±1.96SDd − 1), (2)
where d is the mean difference, and SDd is the standard deviation
of the difference on the log scale, where we corrected for repeated
measurements from the follow-up examinations (Bland and
Altman, 1999). To access the precision, we also calculated the
95% CI for the limits of agreement:
CIlimits of agreement = 100 · (ed±
√
3SD2
d
n − 1). (3)
Clinical follow-up analysis
Clinical follow-up defines its own metric. To assess the
robustness of the MR-AC methods over time (MR-AC-to-
MR-AC) we calculated the within AC modality absolute and
percentage changes of BTV, TMEAN/B and TMAX/B between the
baseline and follow-up examinations, respectively, and compared
each AC method to the reference CT-AC-to-CT-AC change.
Similarly, to simulate the consequences of changing AC methods
during the course of clinical follow-up we compared the reference
CT-AC-to-CT-AC change with the CT-AC-to-MR-AC change
and the MR-AC-to-CT-AC change. For the longitudinal metric
we use the same clinical acceptance criteria as for the single time
point metric.
A specialist in nuclear medicine (IL) evaluated every
tumor delineation visually from the most promising technique
(RESOLUTE) compared to CT-AC, and evaluated all metrics
that deviated from any defined criteria in relation to the
clinical history to identify patients in which this could have
impact.
RESULTS
Accuracy of Attenuation Map Resolute in
the Presence of Metal Implants
RESOLUTE was able to correctly identify and image the
inserted titanium implants with one exception, a titanium mesh
dominated by signal voids (Figure 1), which was excluded from
group analysis. There were 3 scans with an inserted mesh. Visual
reading showed that RESOLUTE had the tendency to build up
a denser and larger representation of the titanium clamp by
1–3mm that is apparent from CT-AC (Figure 2).
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FIGURE 2 | Comparison of CT and RESOLUTE my-maps. Co-registered images from a patient [F, 65 y/o, glioblastoma multiforme (WHO IV)] examined twice within
80 days illustrating good my map repeatability.
Accuracy of Pet SUV and Diagnostic
Metrics
The quantitative accuracy of the AC methods can be assessed
in Figure 3, and qualitatively in Supplementary Figure 1 for a
representative patient. RESOLUTE recovers the tissue activity
concentration (kBq/mL) of the TMAX value, and in the TMEAN
and background VOI’s nearly 100% compared to the reference
CT-AC. The relative error of TMEAN was on average −1.9 ±
1.9% (max: −7.6%) using RESOLUTE (Supplementary Table 1).
In comparison, the average error for Dixon was −14.9 ± 5.2%
(max:−29.3%) and−7.2± 3.1% (max:−16.9%) for UTE.
When using RESOLUTE 5 out of 68 studies exceed our
acceptance criteria of TMAX/B difference<±0.1 or 5%, TMEAN/B
< ±0.05 or 5%, and BTV < ±2mL or 10% (Figures 4, 5). In
these 5 patients the largest difference for TMAX/B was a decrease
from 2.53 to 2.39 (6%) and for BTV in an other patient was an
increase from 40.0 to 47.9mL (20%) (Supplementary Figure 2).
Characteristically the direction of change in TMAX/B and BTV
always correlated, and in all cases BTV differences could be
assigned to a uniform expansion or erosion of 1–2 voxels around
the periphery indicating that the differences were caused by the
estimation of activity in the background region. None of the
patients changed diagnostic category neither by clinical context,
nor by the a priori limits of TMAX, because of the differences in
FET-PET metrics by RESOLUTE rather than CT-AC. The five
studies also exceeded our acceptance criteria when using Dixon
or UTE. In total, 46 of the 68 studies exceeded our acceptance
criteria for TMEAN/B, TMAX/B or BTV using Dixon, and 26/68
using UTE.
Comparing the diagnostic measure, TMAX/B, with CT-AC
between the different AC methods, we found an average
difference of 0.014 (N.S.) and a maximal difference of 0.21 using
RESOLUTE (Figure 4). The average difference was 0.046 (max:
0.76) using Dixon and 0.010 (max: 0.51) using UTE. The relative
difference was smaller with RESOLUTE, with 95% of the patients
within 5% of CT-AC (Table 2 and Supplementary Figure 3),
compared to within 16% using Dixon and 10% using UTE. A
paired t-test found a statistical significant difference between the
TMAX/B measures found with Dixon and CT-AC (p < 0.001).
The change in AC using Dixon relative to the true classification
measured with CT-AC caused six patients to change category
from reactive tissue to the equivocal group (N = 1) or from
the equivocal group to active tumor tissue (N = 5). The overall
same result is obtained with TMEAN/B in terms of improved
performance by RESOLUTE, however, all but three patients using
Dixon are within our acceptance criteria.
The absolute difference relative to CT when measuring BTV
was 0.7 ± 1.9mL (N.S) using RESOLUTE, where it was 5.3 ±
10mL using Dixon, and 1.7 ± 3.7mL using UTE (Figure 5).
Also for this metric, the variation was significantly reduced
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FIGURE 3 | FET-PET tissue activity concentration plot for max tumor (top),
mean tumor (middle), and mean background (bottom) values from 3
attenuation correction methods vs. CT reference standard.
using RESOLUTE. The 95% limits of agreement for this metric
is outside the 10% acceptance limit for all MR-AC methods
(Table 2), due to the effect of the smaller tumors (<20mL) on
the relative difference measure. This also effects the 95% CI and
results in all MR-AC methods being significantly different from
CT-AC (p < 0.05).
The tumor delineation precision was improved, from Jaccard
index of 0.70 ± 0.17 using Dixon, to 0.83 ± 0.13 using UTE
and 0.90 ± 0.07 using RESOLUTE. The shape deviation analysis
found that 37% of the patients had distinct warps in the outline
of the BTV of more than 1mL (average 6mL) using Dixon, and
11% of the patients using UTE (average 2mL). These deviations
were in the shape of relative expansion toward areas with
overestimated tissues in the attenuationmap, and relative erosion
close to the skull. Using RESOLUTE, none of the patients had
tumors with shapes that were significantly different compared to
the tumor delineated using CT. An example of the effects of AC
method on tumor delineation is illustrated in Figure 6.
The peak location of TMAX used for biopsy guidance was in
general agreement across all ACmethods. However, in 15% of the
patients, the peak location changed position >10mm compared
to CT-AC using Dixon, in 5% when using UTE, and only in 1%
using RESOLUTE. In this case the activity peak moved along a
low crescent shaped uptake along a resection cavity.
Follow-Up Examinations
Fourteen of the patients had a PET/MRI follow-up examination
at 5 days to 4 months (average: 66 days) following the first.
Pairwise inspection showed that the two RESOLUTE AC maps
were well matched (Figure 2). The within AC modality percent
change in TMEAN/B and TMAX/B between the baseline and
follow-up examinations are shown for each of the AC methods
(MR-AC-to-MR-AC) evaluated relative to CT-AC-to-CT-AC in
Supplementary Table 2. The within AC modality changes of
TMEAN/B and TMAX/B were found to be congruent and within
criteria for each AC method in almost all patients. In 1 patient
the CT-AC-to-CT-AC decrease in TMAX/B was 13% (−0.4)
while MR-AC-to-MR-AC UTE found an increase of 3% (+0.1).
In further 4 patients had absolute differences in TMAX/B or
TMEAN/B, which exceeded our criteria of 5%-points from the
reference, with errors above 0.1 using Dixon and UTE, but
below 0.2. For BTV 5 patients using Dixon and 3 patients using
UTE exceeded our criteria of 10%-points from the reference
(Supplementary Table 3). In two patients using Dixon and in
two using UTE BTV changes were in increased as opposed
to decreased or stable in CT-AC-to-CT-AC, or vice versa. The
within AC modality for TMEAN/B, TMAX/B and BTV follow-up
changes were consistent in CT-AC-to-CT-AC and MR-AC-to-
MR-AC RESOLUTE.
The between AC modality changes when CT-AC, and not the
same MR-AC, was used as baseline for follow-up the deviations
in metric were notably more pronounced. We found that 86%
of the patients using Dixon, and 50% of patients using UTE,
exceeded our criteria of more than either 10%-point in BTV or
5%-point in TMAX/B (Supplementary Tables 4, 5). Conversely
when using MR-AC as baseline and CT-AC in follow-up there
were differences above criteria in 71% of the Dixon patients and
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FIGURE 4 | Bland-Altman plot of TMEAN/B (left) and TMAX/B (right) for each of the three MR-AC methods against the reference standard CT-AC. To simulate the
clinical impact of the metrics in evaluating reactive changes vs. tumor recurrence 3 intervals have been labeled along the x-axis. The gray shaded areas define an
interval of ambiguity. The black lines indicate the acceptance criteria of TMEAN/B of ±0.05 or 5% and TMAX/B of ±0.1 or 5%, respectively. Points that exceed the
criteria have been colored. Note the difference on the axes. The solid gray line indicates the mean value.
43% of the UTE patients (Supplementary Tables 6, 7). In the
most extreme case CT-AC-to-CT-AC yielded a BTV increase of
5% (15.4 to 16.1mL), which became a 54% increase (15.4 to
23.7mL) if using CT-AC-to-Dixon-AC, and a decrease of 28%
(22.5 to 16.1mL) inDixon-AC-to-CT-AC. All RESOLUTE results
were within the given criteria except for one patient. Overall, the
metric TMEAN/B seemed more robust to changes in AC method
than TMAX/B.
Discussions
The two most obvious target groups for clinical PET/MRI of
the brain is dementia and neuro-oncology patients (Bailey et al.,
2015; Barthel et al., 2015; Fink et al., 2015; Werner et al.,
2015; Henriksen et al., 2016a,b). Unfortunately, the development,
implementation, dissemination, and adaption of PET/MRI has
been hampered by the systematic underperformance of an
essential correction for accurate PET quantification in the
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FIGURE 5 | Bland-Altman plot of biological tumor volume (BTV inmL) for each
of the three MR-AC methods against the reference standard CT-AC. A single
point has been moved (from y = 59 to 30) to fit within the y-axis on the Dixon
plot. The black lines indicate the acceptance criteria of BTV of ±2mL or 10%.
Points that exceed the criteria have been colored. The solid gray line indicates
the mean value.
TABLE 2 | Summary of the relative %-difference* to the reference CT-AC of each
clinical metric for the MR-AC methods.
Measured
parameter
values
Mean % difference 95% lower
limits of
agreement
95%upper
limits of
agreement
Mean 95% CI P
DIXON
TMEAN/B 0.1 −0.4 to 0.6 0.65 −4.0 4.5
TMAX/B 2.6 1.1 to 4.1 <0.001** −9.0 15.7
BTV 32 21 to 43 <0.001** −34 163
UTE
TMEAN/B −0.1 −0.3 to 0.2 0.60 −2.0 1.9
TMAX/B 0.9 −0.1 to 1.9 0.08 −7.0 9.5
BTV 11 5 to 17 <0.001** −27 68
RESOLUTE
TMEAN/B 0.1 −0.1 to 0.2 0.58 −1.3 1.4
TMAX/B 0.4 0.0 to 0.9 0.06 −3.3 4.3
BTV 4 1 to 6 0.01** −16 28
*Exponentiation was applied to results from analyses on log scale, and results were
expressed as percentages.
**Indicates a statistical significant (P < 0.05) found by a paired t-test.
CI = 95% confidence interval for mean difference.
BTV is measured in mL.
brain (Andersen et al., 2014; Dickson et al., 2014). The
clinical consequences of the imperfect AC solutions provided
by the scanner vendors have been insufficiently understood and
documented leading to reluctance in a full-scale routine clinical
adaptation, despite FDA approval. This has lead to a rather long
“discovery phase” with a wide range of AC techniques being
developed, but usually tested within small studies with a limited
number of patients or scans and using metrics that were not in
routine clinical use. This has further reduced the confidence in
PET/MRI in the clinical and research neuroscience community.
In the present study we have evaluated the effects of 3 MR-AC
methods on the clinical metrics used in our institution for FET-
PET in a large group of brain tumor patients investigated with
PET/MRI scanning.
This category of patients is well suited: (1) It is one of the
PET/MRI targets groups; (2) they are particularly challenging in
the face of gross anatomical deformation, and MRI susceptibility
artifacts from titanium alloy implants, which our patients
were retrospectively selected for: (3) it is less dependent on
a clinical reading, (4) there are well established clinical semi-
quantitative metrics, and (5) the consequences of deviation may
be meaningfully interpreted in a clinical context. The latter point
is important, as imaging was not followed by biopsy confirmation
and we, thus, cannot estimate the diagnostic accuracy of any of
the AC methods.
Overall, we found our new RESOLUTEmethodology to be the
AC method that most robustly reproduced the CT-AC clinical
metrics per se, during follow-up, and when interpreted into
defined clinical use cut-off criteria and into the patient history.
The titanium alloy clamp, that were present in all patients,
only generated a limited signal void in the UTE TE images within
the width of the skull which meant that a valid attenuation
map without artifacts could be calculated in all scans using
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FIGURE 6 | Relative differences in tumor delineation by attenuation correction methods in multifocal Astrocytoma grade II patient overlaid onto FET PETCT fused with
T1w MPRAGE. (A) Shows sagittal orientation, (B) Shows expanded anterior tumor section. RESOLUTE has the best overlap with CT-AC, while Dixon and UTE is
significantly overestimated, because of difficulties in defining AC in the skull base and nasal cavity. BTV (mL)/Jaccard Index relative to CT (%) was for CT: 44, Dixon:
75/0.59, UTE: 61/0.72, RESOLUTE: 48/0.89.
RESOLUTE (e.g., seen in Figure 2). However, they appeared
denser and larger than on CT-AC laterally expanding the BTV
for tumors 1–2mm immediately under a clamp. As present CT-
AC techniques do not include a value for metal, CT-AC will
classify the clamps as bone and consequently underestimate the
attenuation value. Thus, the lateral tumor delineation may be
more correct with RESOLUTE than with CT-AC. Unfortunately,
this cannot be confirmed with reference to the tumor structure
because of the MRI susceptibility artifacts. In a clinical setting
this difference will add a smaller volume contribution to the BTV
(<1 cm3), and can explain some of the larger variabilities in the
RESOLUTE-AC BTV measure, but when known this pit-fall can
be compensated for in the reading. In 3 scans, patients had a
titanium alloy mesh cranioplasty to cover calvarial craniotomy
defects, producing unacceptable susceptible artifacts in 1 patient
(Figure 1). This patient was subsequently removed from analysis.
Furthermore, even though the low-dose CT is obtained at the
same day as PET/MRI, we do expect some local registration
errors when registering the CT to the MR images. Adding to
the misrepresentation of metal, CT must be considered a silver
standard here.
The strength of the RESOLUTE methodology is that it is
based on an image-derived measurement and is thus able to
model abnormal patient anatomy providing that the information
is present in the MR images, e.g., in post-operative subcutaneous
soft tissue swelling (Supplementary Figure 4). The atlas-based
approaches are for dedicated use in a circumscribed, well-defined
patient population of which it may be reasonably assumed that
the anatomical structures of a patient new to the atlas can be
modeled (Burgos et al., 2014; Izquierdo-Garcia et al., 2014). This,
unfortunately, seriously restricts the flexibility of PET/MRI as
a clinical and research tool and is the most serious flaw in the
atlas-based approach. The selection of an atlas-based approach
will never satisfy the needs of a diverse clientele for PET/MRI
scanning and will always necessitate the implementation of
additional AC-methods or atlases for subjects not represented
in the primary atlas. Performance of the atlas or template based
AC-methods in their present development state can be expected
to suffer in patients with titanium implants, cranial defects, and
deviant anatomy. Thus, RESOLUTE is a more adaptive tool and
a more attractive option from a practical point of view. A further
strength of RESOLUTE is processing time. The calculation of an
attenuation map can be performed in <5 min. Thus, the quality
of the mapmay be evaluated by the technologist while the patient
is still in the scanner. If there are obvious artifacts alternative
methods such as CT-AC can be introduced before the patient
leaves the department securing an acceptable PET image quality
and limiting patient discomfort.
It has previously been shown that both Dixon and UTE
systematically underestimates PET tissue activity concentration,
which is confirmed in this study (Figure 3). There were no
systematic errors when using RESOLUTE. The largest errors
when using Dixon and UTE are usually close to bone, as this is
not correctly accounted for in either method (Andersen et al.,
2014; Dickson et al., 2014), resulting in a radial gradient from the
surface of the brain toward the center of the brain. These findings
were confirmed also in our patient group (Supplementary
Figure 5). The radial gradient is particularly unfortunate using
the tracer FET as the tumor boundaries are isocontour-defined
dependent on a scan specific threshold from a background area
defined in close proximity to the skull. Thus, we found tumor
border changes relative to the gradient, expanding in the center,
eroding near the skull. More serious than the gradient effects
were actual nodular shape deformations of above 1mL. This
was found in 37% of the patients examined using Dixon and
in 11% using UTE, and may critically compromise the accuracy
and robustness of tumor delineation performed in planning of
radiotherapy (Piroth et al., 2012; Gotz and Grosu, 2013; Moller
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et al., 2016) and of neurosurgical intervention (Klasner et al.,
2015; Albert et al., 2016). The largest BTV deviation from CT-AC
for RESOLUTE was caused by a 1–2 voxel deviation surrounding
the tumor. For two patients, this resulted in an increased BTV
compared to CT-AC of 8mL (+20%) and −3mL (−40%),
respectively. In the first patient this could be attributed to the
irregular, large and diffuse tumor borders (Supplementary Figure
2). The difference, however, is sufficiently large to be a concern
if considering tumor re-irradiation, where the planning target
volume (PTV) consists of margins of only 2–3 mm added to the
gross tumor volume (GTV; Grosu et al., 2005; Moller et al., 2016).
Our patient cohort predominantly consisted of FET-PET
scans with clear indications of viable tumor tissue of which 29
(43%) had a TMAX/B ratio above 3.0. For these patients, even an
underestimation of the ratio of up to 0.6 would not change the
clinical reading. Thus, only six patients changed clinical category
when using Dixon, and none using UTE and RESOLUTE despite
the large quantitative errors.
The statistical analysis of the TMEAN/B, TMAX/B, and
BTV assumes log normal distributions. This assumption was
confirmed by model control. There were, however, more outlier
points than expected when assuming normal distributions, which
could result in the limits of agreement being slightly too
small.
The results of the follow-up analysis showed that for the
majority of the patients a similar conclusion of treatment
response regardless of the attenuation method employed would
be reached (Supplementary Tables 2, 3). However, the conclusion
based on BTV is misleading for two patients using Dixon and two
patients using UTE. One of the patients has a decrease in BTV
after treatment of 10%, where UTE instead finds an increase of
50%. Such errors could potentially result in the termination of
an effective treatment. In contrast, there were no such outliers
when using RESOLUTE, but a larger follow-up study should
further confirm this. The results of analysis where the ACmethod
was changed in either the baseline or the follow-up examination,
and CT-AC was used in the other, illustrated the robustness
of RESOLUTE, and indicated that RESOLUTE can potentially
replace the CT-AC even in longitudinal studies.
CONCLUSION
The present study performed in a large group of post-
surgical brain tumor patients using simultaneously acquired
FET PET/MRI imaging revealed that our new brain MR-AC
method RESOLUTE is able to robustly produce attenuation
maps even when titanium alloy clamps are present. The MR
images were unpredictable in the case of titanium alloy mesh
implants, and visual inspection of the attenuation maps to detect
signal voids is still required. The clinical metrics was within
acceptable limits of the reference CT-AC, and is an improvement
over the vendor-provided Dixon and UTE methods. RESOLUTE
is especially suitable for brain tumor patients, as these often
present with abnormal anatomy where other methods based on
atlas or template information might fail. In our unit we are
sufficiently confident in these results to have abandoned the
routine use of CT-AC and adapted RESOLUTE-AC for routine
clinical PET/MRI FET brain imaging in the adult patients.
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